Page 219«..1020..218219220221..230240..»

Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study – Targeted Oncology

Posted: August 22, 2022 at 2:09 am

The first of approximately 97 patients with classical Hodgkin lymphoma (cHL) has been administered the combination of TT11 and nivolumab (Opdivo) in the phase 1b ACTION study (NCT05352828).1

TT11 is an experimental autologous CD38-chimeric antigen receptor (CAR) T-cell therapy that is being developed for the potential treatment of relapsed or refractory cHL as a single agent and in combination with other therapies. The agent had been granted a regenerative medicine advanced therapy designation by the FDA and the PRIME scheme by European Medicines Agency.

Initiation of this phase 1b clinical trial marks an important milestone for our autologous CD30- CAR T program as we now have the opportunity to evaluate TT11 in combination with nivolumab as a potential second-line treatment for relapsed or refractory classical Hodgkin lymphoma, stated John Ng, chief technology officer and acting chief operating office and of Tessa Therapeutics, in a press release.

Dosing in the study comes after single-agent results were reported from the phase 2 CHARIOT study (NCT04268706). In heavily-pretreated patients with cHL, promising efficacy and tolerable was shown with TT11 monotherapy. The overall response rate observed was 71.4% with a complete response rate of 57.1% In terms of safety, the most common toxicities were hematologic toxicities.2

Data from our ongoing clinical program investigating TT11 as a monotherapy treatment for later lines of classical Hodgkin lymphoma has demonstrated the CAR T therapy to be safe with promising measures of efficacy. We now welcome the opportunity to capitalize on this clinical progress by investigating TT11 as a second-line combination therapy, which offers the opportunity to greatly increase the patient population who could potentially benefit from this course of care, added Ng.1

In the multicenter, open-label, single arm ACTION study, patients will receive 4 cycles of TT11 at 2 x 108 cells/m2 in combination with nivolumab 480 mg or 6 mg/kg 4 times per week, fludarabine 30 mg/m2/day for 3 days, and bendamustine 70 mg/m2/day for 3 days after a successful leukapheresis to produce CD30 CAR T cells.3

The primary end point being explored in the study is the safety of autologous CD30 CAR T cells determined by dose-limiting toxicities. The secondary end points of the study include anti-tumor activity, overall response rate, duration of response, and progression-free survival. Other outcome being investigated include overall survival and pharmacokinetics.

Male or female patient aged 12 years or older are eligible to enroll if they have relapsed/refractory cHL following failure on standard frontline therapy, at least 1 measurable lesion, and adequate hematologic, renal, hepatic function and other laboratory tests. Patients are required to have an ECOG performance status of 0 or, a life expectancy of > 12 weeks, and no active infection at the time of screening.

Patients are excluded from the study if they have received prior treatment with salvage therapy for relapsed/refractory cHL, investigational CD30 CAR T cells. Moreover, patients receiving other investigational therapies, live vaccines, or immunosuppressive agents are not eligible for the study. Comorbidities that may interfere with study treatment and hypersensitivity to study drugs are also mentioned in the exclusion criteria.

The ACTION study is actively recruiting patients with relapsed/refractory cHL at study sites in California, Florida, North Carolina, and Texas.

REFERENCES:

1. Tessa Therapeutics doses first patient in phase 1b clinical trial investigating TT11 in combination with nivolumab for the treatment of relapsed/refractory classical hodgkin lymphoma (cHL). News release. August 17, 2022. Accessed August 18, 2022. https://bit.ly/3AteZem

2. Tessa Therapeutics announces positive data from phase 2 trial of autologous cd30-car-t therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting. News release. August 14, 2021. Accessed August 18, 2022. https://bit.ly/3Qy0OKL

3. Phase 2 study evaluating autologous CD30.CAR-T cells in patients with relapsed/refractory hodgkin lymphoma (CHARIOT). Clinicaltrials.gov. Updated April 5, 2022. Accessed August 18, 2022.

See original here:
Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study - Targeted Oncology

Posted in Regenerative Medicine | Comments Off on Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study – Targeted Oncology

Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 – EurekAlert

Posted: August 22, 2022 at 2:09 am

image:The ARDD Meeting 2022 will be hosted on August 29 - September 2, 2022 view more

Credit: Insilico Medicine Hong Kong Limited

August 18, 2022 Marco Quarta, Ph.D., will present the latest research on the topic From Single Cell AI-enabled Discovery of Cellular Senescence to Targeted Senolytic Drug Development at the worlds largest annual Aging Research and Drug Discovery conference (9th ARDD). Dr. Quarta is the CEO and Co-founder at Rubedo Life Sciences.

Marco co-founded and leads Rubedo Life Sciences driving its mission to develop treatments for age-related diseases and extend healthspan by selectively targeting pathological cells involved in the biological aging process. As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine. He is backed by over 20 years of research with a track record of scientific publications in top tier journals. Marco is an inventor and entrepreneur, he co-founded and led the international biotech umbrella organization Young European Biotech Network (YEBN), and later joined the European Federation of Biotechnology (EFB) executive board.

Marco Quarta founded and led the biotech company WetWare Concepts in Europe. In California, with the Stanford colleague Prof. Vittorio Sebastiano he also co-founded Turn Biotechnologies based on their work on epigenetic reprogramming of cellular aging, where he served as CSO and he is a Board Director. Quarta sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly program in regenerative medicine. He is in the advisory and research board at the Center for Healthcare Innovation (CHI). He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University. Quarta keeps fostering and championing high standards of compliance, ethics and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at http://www.agingpharma.org. Please review the conference proceedings for 2019, 2020 and 2021https://www.aging-us.com/article/203859/text .

Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2022 conference is the best yet with top level speakers from around the globe. Im extremely excited to be able to meet them in person at the University of Copenhagen in late summer. said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place both offline and online, and it was a great success. I am particularly excited that being a part of the ARDD2022 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field. said Daniela Bakula, Ph.D., University of Copenhagen.

Many credible biopharmaceutical companies are now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we organize for nine years in a row. This conference is now the largest in the field and is not to be missed, said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine and Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the Longevity Medicine course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.

About Scheibye-Knudsen Lab

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

About Deep Longevity

Deep Longevity has been acquired by Edurance RP (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/

About Endurance RP (SEHK:0575.HK)

Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert

Posted in Regenerative Medicine | Comments Off on Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 – EurekAlert

3D Systems announces appointment of Dr. Toby Cosgrove and Dr. Bon Ku as members of its Medical Advisory Board – TCT Magazine

Posted: August 22, 2022 at 2:09 am

3D Systems announced on August 18 the appointments of Dr. Toby Cosgrove, former President and Chief Executive Officer of the Cleveland Clinic, and Dr. Bon Ku, Director of the Health Design Lab at Thomas Jefferson University.

Dr. Cosgrove and Dr. Ku become the fourth and fifth members of 3D Systems recently established Medical Advisory Board (MAB). The two join former Health and Human Services Secretary Alex Azar, Dr. Stephen K. Klasko, and former U.S. Secretary of Veterans Affairs David J. Shulkin as members of the advisory board.

The primary mission of the board is to provide strategic input, guidance and recommendations for the companys expanding efforts in regenerative medicine.

Dr. Cosgrove has been affiliated with the Cleveland Clinic healthcare system for nearly 50 years. He served as President and CEO from 2004 to 2017 and is currently an Executive Advisor to the Clinic.

As President and CEO, Dr. Cosgrove oversaw a 6 billion USD annual revenue institution comprised of the Cleveland Clinic, over 20 Ohio-based hospitals, family health centres and surgical facilities, as well as Cleveland Clinic affiliates in other U.S. states and internationally.

Dr. Cosgrove was a cardiac surgeon in Cleveland and served as Chairman of the Department of Thoracic and Cardiovascular Surgery from 1989 to 2004 at the clinic. He has performed over 22,000 operations over the course of his career.

Dr. Bon Ku has enjoyed a career as both a practicing medical clinician and as a proponent of using technology-based innovations to solve pressing healthcare challenges. Dr. Ku is the Marta and Robert Adelson Professor of Medicine and Design at Thomas Jefferson University as well as an emergency physician at the Universitys Sidney Kimmel Medical College.

Dr. Ku has used modern technological tools such as virtualisation, digital modelling, prototyping and additive manufacturing. He is the co-founder and Director of Thomas Jefferson Universitys Health Design Lab. The lab works with medical students, researchers and physicians to develop new medical devices and innovative design concepts for the healthcare sector.

The Health Design Lab led by Dr. Ku features a clinical 3D printing and bioprinting lab and is home to the JeffSolves MedTech initiative. This serves as a centre for the incubation and commercialisation of new medical technologies.

Dr. Ku has written a number of peer-reviewed publications focusing on the application of 3D-printed medical devices and digital models to improve surgical outcomes, optimise treatments and make advancements in personalised medicine.

3D Systems President and CEO Dr. Jeffrey Graves said: We are exceptionally pleased to welcome Dr. Cosgrove and Dr. Ku to our Medical Advisory Board. These two professionals have impeccable track records of combining hands-on medical practise experience with a clear passion for utilising innovative approaches and modern technology to transform healthcare outcomes.

Graves continued, saying: Both Dr. Cosgrove and Dr. Ku will be uniquely positioned to advise 3D Systems as we build a world-class regenerative medicine business and pursue 3D printing-based advancements in areas such as accelerated pharmaceutical development, human tissue and organ printing, medical device innovation and personalised medicine.

There have been a lot of acquisitions from major 3D printing companies so far in 2022, with3D Systems among those to have added new strings to its bow. The company recentlyacquired material jetting firm dp polar, while taking over both Titan Robotics and Kumovis earlier in the year.

3D Systems also recently announced a partnership with Fleet Space Technologies, and produced parts for the Alpine F1 team for the 2021 and 2022 seasons.

Want to discuss? Join the conversation on theAdditive Manufacturing Global Community Discord.

Get yourFREE print subscriptionto TCT Magazine.

Here is the original post:
3D Systems announces appointment of Dr. Toby Cosgrove and Dr. Bon Ku as members of its Medical Advisory Board - TCT Magazine

Posted in Regenerative Medicine | Comments Off on 3D Systems announces appointment of Dr. Toby Cosgrove and Dr. Bon Ku as members of its Medical Advisory Board – TCT Magazine

These Scientists Say They’ve Reversed Aging in Human Cells by 30 Years – Best Life

Posted: August 22, 2022 at 2:09 am

Most of us wish we could turn back the clock in some way, to retain or reclaim some of the benefits of youth, whether it's looking younger or regaining some element of youthful prowess. Researchers say they've discovered a way to do just that in skin cells: to reverse their age so they look and behave like cells that are 30 years younger. Read on to find out how they did itand how Dolly the sheep is involvedand what the implications could be for the future of aging.

In a study recently published in the journal eLife, researchers said they had discovered a way to reverse aging in human skin cells by 30 years. Their process, called "maturation phase transient reprogramming," refreshes older cells to partly restore their function and to renew their biological age, while maintaining the cells' specific type and function.

In their experiments, the BBC reports, the scientists rejuvenated a 53-year-old woman's skin cells so they looked and behaved like those of a 23-year-old. Their technique evolved from the technology that was used to create Dolly the cloned sheep in 2007the process used to create stem cells, in which normal cells of a specific function are erased and rebooted to become cells of any type.

The scientists subjected cells to that process, but stopped halfway through. So instead of becoming stem cellsinfant blank slates, so to speakthey became younger versions of themselves.

Although the research is only in its early stages, if the findings hold up, they could revolutionize regenerative medicinea field that aims to repair or replace cells, including old ones. Successful regenerative medicine depends on cells not just looking younger, but functioning like young cells too. The researchers found that the functionally younger skin cells they created were better able to produce collagen, and better responded to wound healing sites.

If those results can be replicated in other kinds of cells, a similar process might be able to rejuvenate aging bones, muscles, and tendons, or forestall the diseases of an aging brain, including dementia and Alzheimer's.

ae0fcc31ae342fd3a1346ebb1f342fcb

"This work has very exciting implications," said Wolf Reik, a molecular biologist with Altos Labs Cambridge Institute. "Eventually, we may be able to identify genes that rejuvenate without reprogramming, and specifically target those to reduce the effects of aging. This approach holds promise for valuable discoveries that could open up an amazing therapeutic horizon."

"Our results represent a big step forward in our understanding of cell reprogramming," said Dr. Diljeet Gill, a postdoctoral researcher in Reik's lab. "We have proved that cells can be rejuvenated without losing their function and that rejuvenation looks to restore some function to old cells. The fact that we also saw a reverse of aging indicators in genes associated with diseases is particularly promising for the future of this work."

Follow this link:
These Scientists Say They've Reversed Aging in Human Cells by 30 Years - Best Life

Posted in Regenerative Medicine | Comments Off on These Scientists Say They’ve Reversed Aging in Human Cells by 30 Years – Best Life

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO – GlobeNewswire

Posted: August 22, 2022 at 2:09 am

PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend.

Dr. Richard Caruso made an impact on not only the medical technology industry, but more importantly, on the countless lives around the world who have benefited from the products and technologies that Integra LifeSciences has today, said Stuart Essig, chairman of the board at Integra LifeSciences. His vision, transformative ideas and entrepreneurial spirit have revolutionized the way surgeons treat their patients in the field of regenerative medicine.

Dr. Caruso founded Integra LifeSciences in 1989 with a vision that the human body could be enabled to regenerate many of its own damaged or diseased tissues, paving the way for a new discipline back then known as regenerative medicine. Through his vision, Integra became the first company to develop and bring to market a tissue regeneration product, Integra Dermal Regeneration Template, which was approved by the FDA in 1996 as a skin replacement system with a claim for regeneration of dermal tissue for the treatment of life-threatening burns and repair of scar contractures. That technology led to the development of DuraGen Dural Graft Matrix, for repair of the dura mater, the protective covering of the brain after cranial and spine surgery, and NeuraGen Nerve Guide, which creates a conduit for axonal growth across a severed nerve.

Dr. Caruso served as Integra's chairman from 1992 until 2011, and served as CEO from 1992 to 1997. In addition, he served on the Board of Susquehanna University and the Baum School of Art. Dr. Caruso received his B.S. degree from Susquehanna University, an M.S.B.A. degree from Bucknell University, and a Ph.D. degree from the London School of Economics, University of London. He was also the founder and director of The Uncommon Individual Foundation, a non-profit foundation that encourages individuals to form and follow their dreams of personal success and become the entrepreneurs of their personal lives.

About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel, Aurora, Bactiseal,BioD, CerebroFlo, CereLinkCertasPlus, Codman, CUSA, Cytal, DuraGen, DuraSeal, Gentrix, ICP Express, Integra, Licox, MAYFIELD, MediHoney, MicroFrance, MicroMatrix, NeuraGen, NeuraWrap, PriMatrix, SurgiMend, TCC-EZand VersaTru. For the latest news and information about Integra and its products, please visitwww.integralife.com.

Investor Relations Contact:Chris Ward(609) 772-7736chris.ward@integralife.com

Media Contact:Laurene Isip(609) 208-8121laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe4238dd-d2f8-487f-8f14-19e855e9b041.

See the rest here:
Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO – GlobeNewswire

Pair of Hopkins teams receive $200K in technology grants – Maryland Daily Record

Posted: August 22, 2022 at 2:06 am

Two Johns Hopkins research teams have received technology development grants totaling approximately $200,000 through the Louis B. Thalheimer Fund for Translational Research.

A total of 14 researchers applied for the latest funding round. Finalists pitched their proposals virtually in late May to an outside panel of independent researchers and investors, innovation executives and venture investors.

Established through a $5.4 million gift from businessman and philanthropist Louis B. Thalheimer, the fund provides seed funding for proof-of-concept and validation studies of Johns Hopkins technologies.

Since 2016, the Thalheimer Fund has awarded more than $1.7 million to 20 projects at Johns Hopkins. Grants range from $25,000 to $100,000 and all recipients have formally reported their inventions to Johns Hopkins Technology Ventures (JHTV).

Previous Thalheimer winners are developing a faster and more accurate wayto diagnose epilepsy; an oral therapy for patientssuffering from inflammatory bowel disease; and a longer-lastingtreatment for wrinkles and migraines, among other technologies.

This years grantees are:

Urinfo: Holographic Urine Monitoring to Prevent Catheter-Associated Urinary Tract Infections

Principal investigator:Nicholas J. Durr, assistant professor in the Department of Biomedical Engineering

The pitch:Real-time patient monitoring for early signs of potential infection

Catheter-associated urinary tract infections (CA-UTIs) are the most common hospital-based infections. A significant risk factor is prolonged used of a catheter, and nearly 80% of the 500,000 annual cases are thought to be preventable with timely intervention.

The current approach to managing CA-UTIs is mostly reactive, monitoring for symptoms followed by diagnostic confirmation. Durr and his collaborators have invented a lens-free imaging device that can provide continuous, noninvasive analysis of urine to with the potential to detect early signs of CA-UTI.

A flow chamber sits between the catheter and urine bag that is continually imaged, from which the urines bacterial load is determined through an algorithm. If the load surpasses a predefined threshold or displays a worrisome trend, the clinician is alerted. Flow chambers would be changed for each patient, while the rest of the system would be reusable.

JHTV is pursuing patent protection for the technology. The team has developed a benchtop prototype of the system and part of the Thalheimer funding will go toward developing a bedside prototype. They also will use the grant to collect initial data to prepare a federal Small Business Innovation Research grant application.

Cytoplasmic Transfer Cell Therapy for Vision Repair in Retinitis Pigmentosa

Principal investigator:Mandeep S. Singh,assistant professor of ophthalmology and genetic medicine at the Johns Hopkins Wilmer Eye Institute

The pitch:A novel way to treat multiple inherited retinal diseases at once.

Inherited retinal diseases (IRDs) cause vision loss in approximately one in 4,000 people and are caused by a mutation in any one of about 300 genes expressed in photoreceptor cells of the retina. Gene therapies are in development to treat more than 25 individual IRD gene mutations. But Singh, working with Robert Johnston, Ph.D., an associate professor in the Department of Biology at The Johns Hopkins University, is developing a new treatment modality, cytoplasmic transfer cell (CTC) therapy, that has the potential to treat the majority of IRDs with one off-the-shelf product.

CTC therapy involves generating differentiated photoreceptor cells from human pluripotent stem cells, cells that can be developed into any type of human cell, that are then administered to patients. Early observations suggest CTC treatment may permanently restore vision with just one treatment. The team is initially focusing on treating autosomal recessive retinitis pigmentosa (ARRP), a progressive hereditary disorder which accounts for 35% of IRDs.

JHTV is pursuing patent protection for the technology. Singh is planning to form a startup around the technology and has met potential investors with the help of Sashank Reddy, JHTVs medical director. The Thalheimer funding will go toward hiring staffers to help culture CTC cells and continue testing.

View post:
Pair of Hopkins teams receive $200K in technology grants - Maryland Daily Record

Posted in Maryland Stem Cells | Comments Off on Pair of Hopkins teams receive $200K in technology grants – Maryland Daily Record

RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies – BioPharma-Reporter.com

Posted: August 22, 2022 at 2:06 am

The collaboration draws on RoosterBios cell and media products and process development services, coupled with AGC Biologics cell and gene therapy manufacturing capabilities.

The two companies see 'tremendous opportunities' in EVs/exosomes: with projections suggesting a CAGR of 31% (2015-2030) for the market, reaching the $1bn mark by 2027.

In published biomedical research, this subject area now exceeds monoclonal antibodies and liposomes, note the companies: who draw a comparison to a similar pace of growth for monoclonal antibodies during the 1980s ahead of their boom (with this sector now worth around $100bn in global annual sales).

RoosterBio and AGC Biologics believe these research growth rates indicate this cell type is becoming a popular choice amongst developers to help advance the cell and gene product pipeline.

However, access to exosome cell and media development and manufacturing facilities to get treatments into the clinic is still scarce: with the new partnership seeking to bridge this gap and give cell and gene developers end-to-end services.

In the new partnership, Frederick, Maryland-headquartered RoosterBio will use its portfolio of cell and media products to develop robust, scalable processes for human mesenchymal stem/stromal cells (hMSC) and exosome therapies.

These capabilities include genetic engineering of cells and exosomes to express therapeutic targets, upstream processing in both 2D flask and 3D bioreactor systems, downstream purification to achieve desired purity and potency, and comprehensive analytical characterization of the resulting formulated cell or exosome therapy.

Meanwhile, Seattle-headquartered AGC Biologics will contribute its global network to provide full Process Development, cGMP Manufacturing, Quality Control and Regulatory services for pre-clinical and phase I/II clinical trials, with the ability to scale to Phase III and commercial production.

The CDMO has a global network of sites dedicated to cell therapy technologies and processes, including allogenic and autologous systems and techniques.

More details on this partnership will be released in the coming months.

"RoosterBio has a reliable method for producing engineered cells and exosomes that can help developers create life-saving therapies," said Patricio Massera, Chief Executive Officer of AGC Biologics. "When you combine their work and expertise with AGC Biologics' scientific knowledge and global manufacturing services, it creates a comprehensive offering that can help these developers save time and money, and get their treatments in the hands of patients in need."

Tim Kelly, Chief Executive Officer of RoosterBio, said: Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing solutions. This collaboration was conceived to deliver that end-to-end solution for our customers and I am thrilled to partner with AGC Biologics to translate our hMSC and exosome technologies into advanced therapy products that have the potential to bring curative treatments to patients in need.

Excerpt from:
RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies - BioPharma-Reporter.com

Posted in Maryland Stem Cells | Comments Off on RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies – BioPharma-Reporter.com

This Man Set the Record for Wearing a Brain-Computer Interface – WIRED

Posted: August 22, 2022 at 2:06 am

Florian Solzbacher, co-founder and chairman of Blackrock Neurotech, which manufactures the Utah arrays, says the company is testing one thats coated with a combination of parylene and silicon carbide, which has been around for more than 100 years as an industrial material. Weve seen lifetimes on the benchtop that can reach up to 30 years, and weve got some preliminary data in animals right now, he says. But the company has yet to implant it in people, so the real test will be how human tissue reacts to the new formulation.

Making electrodes more flexible could also help reduce scarring. Angles company Paradromics is developing an implant similar to the Utah array, but with thinner electrodes intended to be less disruptive to tissue.

Some researchers are trying out softer materials that may be able to better integrate into the brain than the rigid Utah array. One group, at the Massachusetts Institute of Technology, is experimenting with hydrogel coatings designed to have an elasticity very similar to that of the brain. Scientists at the University of Pennsylvania are also growing living electrodes, hairlike microtissues made of neurons and nerve fibers grown from stem cells.

But these approaches have downsides, too. You can get a rigid thing into a soft thing. But if youre trying to put a very soft thing into another soft thing, thats very hard, Gaunt says.

Another approach is to make the implants smaller, and therefore less invasive. For instance, researchers are testing neurograins, tiny chips the size of a grain of sand that could hypothetically be sprinkled across the cortical surface. But no one has tried dispersing them on a human brain; the system has only been tested in rodents that had their skulls removed.

Some research participants have had their Utah arrays taken out and replaced, but multiple surgeries arent ideal, because each one carries a risk of infection or bleeding at the implant site. Gaunt says surgeons probably wouldnt place a new implant in the exact same place as an old one, especially if theres scarring in that area. But making sure that a replacement is put in the right spot is important because implants in the wrong place could impair the function of the BCI.

Gaunt says it would be better for the external BCI componentsthe processors or software, for instanceto be upgradable, so that patients wouldnt have to undergo multiple surgeries.

Nathan Copeland plays a game using his brain-computer interface.

But in fact, an external part of most BCI systems is actually one of the biggest risks for brain implants. The pedestal that sits atop the skull can cause infection, but its presence is necessary to connect the implanted array to the external computer. For now, Copeland and other research participants have to get plugged into the system via their head pedestals to use their BCIs. (Researchers are working on getting rid of the cables.) For Copeland, its a mild annoyance in exchange for getting to do the things he can do with his BCIalthough he hopes future systems will be wireless and give paralyzed people an even broader range of abilities.

Given the unknowns of BCI longevity, Copeland knows his implant could stop working some day. But he tries not to worry about it. Im super chill about most things. I just go with the flow, he says. That said, he wouldnt turn down an upgrade: In five or 10 years, if there is something that would have significant improvements, I would do the surgery again and just go for it.

Originally posted here:
This Man Set the Record for Wearing a Brain-Computer Interface - WIRED

Posted in Utah Stem Cells | Comments Off on This Man Set the Record for Wearing a Brain-Computer Interface – WIRED

Calendar of events, awards and opportunities – ASBMB Today

Posted: August 22, 2022 at 2:06 am

Every week, we update this list with new meetings, awards, scholarships and events to help you advance your career.If youd like us to feature something that youre offering to the bioscience community, email us with the subject line For calendar. ASBMB members offerings take priority, and we do not promote products/services. Learn how to advertise in ASBMB Today.

The Federation of American Societies for Experimental Biology has launched the Career Advancement and Research Excellence Support (CARES) Program, which provides financial support for caregiving, enabling FASEB society members to continue their scientific training, professional development and career progression. Read the eligibility criteriaand apply.

The International Union of Biochemistry and Molecular Biology is offering $2,000 to graduate students and postdocs displaced from their labs as a result of natural disaster, war or "other events beyond their control that interrupt their training." The money is for travel and settling in. Learn more and spread the word to those who could use assistance.

The American Association for Anatomy has a free on-demand webinar titled "The power of suggestion: How to get and gain influence." It features Adele Cehrs, CEO of the When and How Agency, who explains "when the power of suggestion is most likely to work for individuals and how to use it to your advantage through traditional media and social media channels." As we understand it, AAA membership is not required (but you will have to create an account)to view the webinar. Here's a list of all of AAA's open-access webinars.

It's not too early to start thinking about who among your colleagues deserves recognition as an ASBMB fellow. Fellows are recognized for their contributions to the society and their contributions advancing the molecular life sciences, whether that's through research, education and mentorship, or other forms of service to the scientific community. Learn more.

This in-person meeting will be held Sept. 29 through Oct. 2 in Snowbird, Utah. Sessionswill cover recent advances and new technologies in RNA polymerase II regulation, including the contributions of noncoding RNAs, enhancers and promoters, chromatin structure and post-translational modifications, molecular condensates, and other factors that regulate gene expression. Patrick Cramer of the Max Planck Institute will present the keynote address on the structure and function of transcription regulatory complexes.Learn more.

Researchers at Albion College are conducting a survey about women's experiences with STEM mentors during their undergraduate years. If you'd like to participate, access the surveyhere. Itshould take about 15 minutes to complete. The deadline is Aug. 31.

To be or not to be a postdoc?That is often the question that comes to mind toward the end of graduate school. When thinking about your career path, is a stint as a postdoc the next logical step, or are there other ways to get to your ultimate career destination? In this webinar, part ofthe ASBMB Education and Professional Development Committees Insider perspectives series, established scientists will share their journeys from the end of graduate school to the next stages of their careers, exploretheir decision-making about whether and when to pursue a postdoctoral position, and how they leveraged post-Ph.D. training to enhance their careers. Register.

ASBMB Lipid Research Division Seminar Series

The ASBMB Lipid Research Division features the work of young investigators at noon Eastern on Wednesdays. If you are interested in presenting, please contactJohn Burke. Registeronce to access the whole series.

Aug. 31: New mechanisms of phosphoinositide signaling

Most meetings on epigenetics and chromatin focus on transcription, while most meetings on genome integrity include little attention to epigenetics and chromatin. This conference in Seattle will bridge this gap to link researchers who are interested in epigenetic regulations and chromatin with those who are interested in genome integrity. The keynote speakers are Genevive Almouzni at Institut Curie and John Diffley at the Francis Crick Institute. Learn more.

The ASBMB encourages its members to get involved through service on society committees. Committee members serve three-year terms, which are renewable once, typically from July 1 to June 30. The society strives for equity and inclusion, as well as institutional, geographic and career stage diversity on all of its committees.See eligibility criteria and applyThe followingcommittees have one or more openings and welcome all member types to apply:

The American Physiological Society is hosting a free webinar that will cover polycystic ovary syndrome, an endocrine disorder associated with modestly elevated androgens, and hormone therapy for transmen, which elevates androgens greatly to achieve levels similar to those in cisgender men. The event announcement says: "The role that these two different concentrations play in cardiovascular physiology and pathophysiology remains unclear. Gaps and opportunities in basic research and clinical practice will be highlighted." The speaker will be Licy Yanes Cardozo, a physician-scientist at the University of Mississippi Medical Center. Learn more and register.

The American Society for Investigative Pathology is running a series of young investigator keynote talks through the end of the year. Here's the lineup. Register.

Sept. 21: Selection for a Preferred Threshold Level of PI3K Pathway Activation During Myc-driven Mammary Carcinogenesis Maryknoll Palisoc, Penn State College of Medicine

Oct. 19: Investigating Calcium Dysregulation and Viral Virulence Using Forward and Reverse Genetics Thomas Gebert, Baylor College of Medicine

Nov. 16: Modeling Glut1 Deficiency Syndrome at the Human Blood-Brain Barrier In Vitro Using CRISPR-Cas9 Edited Induced Pluripotent Stem Cells Iqra Pervaiz, Texas Tech University of Health Sciences

Dec. 14: Mechanisms of IL-6-driven Endothelial Dysfunction Ramon Bossardi Ramos, Albany Medical College

In May, the Howard Hughes Medical Institute launched a roughly $1.5 billion program to "help build a scientific workforce that more fully reflects our increasingly diverse country." The Freeman Hrabowski Scholars Program will fund 30 scholars every other year, and each appointment can last up to 10 years. That represents up to $8.6 million in total support per scholar. HHMI is accepting applications from researchers "who are strongly committed to advancing diversity, equity, and inclusion in science." Learn more.

The National Academy of Sciences offers more than a dozen annual awards, and the nomination deadline for all of them is Oct. 3. You can see the full list here, but we want to draw your attention to the NAS Award in Molecular Biology (for a young investigator).

Undergraduate students interested in interning at a U.S. Department of Energy laboratory in the spring must apply by Oct. 5. There are two programs to be aware of: the Science Undergraduate Laboratory Internships program and the Community College Internships program. In both cases, students work at national laboratories on research or technology projects supporting the agency's mission. All full-time students or recent grads are eligible for the first program, and community college students are eligible for the other. These are paid positions. Learn more.

The U.S. Department of Energy has expanded its opportunities for faculty members from historically underrepresented groupsto engage in research at national labs. The Visiting Faculty Program is intended to create partnerships between national labs and two-year colleges, minority-serving institutions and other colleges and universities nationwide. About 50% of participants are from MSI, and one-third of those are from historically Black colleges and universities. The deadline to apply is Oct. 5. Learn more.

The NASA Science Mission Directorate Bridge Program is intended to improve diversity, equity, inclusion and accessibility at NASA and in the broader STEM community. The agency seeks to partner with minority-serving institutions, primarily undergraduate institutions and Ph.D.-granting universities and provide paid research student positions "to transition science and engineering students from undergraduate studies into graduate schools and employment by NASA," according to the announcement. A virtual workshop will be held from Oct. 17 through Oct. 21. You have to formally express interest in attending. Learn more.

Save the date for the ASBMB Career Expo. This virtual event aims to highlight the diversity of career choices available to modern biomedical researchers. No matter your career stage, this expo will provide a plethora of career options for you to explore while simultaneously connecting you with knowledgeable professionals in these careers. Each 60-minute session will focus on a different career path and will feature breakout rooms with professionals in those paths. Attendees can choose to meet in a small group with a single professional for the entire session or move freely between breakout rooms to sample advice from multiple professionals. Sessions will feature the following five sectors: industry, government, science communication, science policy and other. The expo will be held from 11 a.m. to 5 p.m. Eastern on Nov. 2. Stay tuned for a link to register!

The Journal of Science Policy & Governanceand the National Science Policy Network issued a call for papersfor an issue containingpolicy ideas from the next generation of scientists. The submission deadline is Nov. 6. Theyencourage submissions "that highlight policy opportunities and audiences related to the 2022 U.S. midterm elections at the local, stateor national level as well as related foreign policy issues."Read the press release.

The ASBMB provides members with a virtual platform to share scientific research and accomplishments and to discuss emerging topics and technologies with the BMB community.

The ASBMB will manage the technical aspects, market the event to tens of thousands of contacts and present the digital event live to a remote audience. Additional tools such as polling, Q&A, breakout rooms and post event Twitter chats may be used to facilitate maximum engagement.

Seminars are typically one to two hours long. A workshop or conference might be longer and even span several days.

Prospective organizers may submit proposals at any time. Decisions are usually made within four to six weeks.

Propose an event.

If you are a graduate student, postdoc or early-career investigator interested in hosting a #LipidTakeover, fill out this application. You can spend a day tweeting from the Journal of Lipid Research's account (@JLipidRes) about your favorite lipids and your work.

The ASBMB Deuel conference is a must-attend event for leading lipids investigators and for scientists whove just begun to explore the role of lipids in their research programs. This event will bring together a diverse array of people, including those who have not attended Deuel or perhaps any lipid meeting before. The conference is a forum for the presentation of new and unpublished data, and attendees enjoy the informal atmosphere that encourages free and open discussion. Interested scientists are invited to attend and encourage trainees to submit abstracts. Learn more.

#DiscoverBMB is the annual meeting of theAmerican Society for Biochemistry and Molecular Biology.

With a mission to sharethe latest, most impactful research findings in the molecular life sciences, #DiscoverBMB offers an exciting agenda that includes in-person and virtual sessions, talks by the field's foremost experts, interactive workshops on the latest trends, technologies and techniques, and an invigorating exhibition of posters, services and products.

The meeting attracts researchers in academia and industry, educators, trainees and students from across the globe. It offers unparalleled opportunities for collaborating, networking and recruiting.

Learn more.

Link:
Calendar of events, awards and opportunities - ASBMB Today

Posted in Utah Stem Cells | Comments Off on Calendar of events, awards and opportunities – ASBMB Today

Genetics in fiction – Wikipedia

Posted: August 14, 2022 at 2:49 am

Aspects of genetics including mutation, hybridisation, cloning, genetic engineering, and eugenics have appeared in fiction since the 19th century.

Genetics is a young science, having started in 1900 with the rediscovery of Gregor Mendel's study on the inheritance of traits in pea plants. During the 20th century it developed to create new sciences and technologies including molecular biology, DNA sequencing, cloning, and genetic engineering. The ethical implications were brought into focus with the eugenics movement.

Since then, many science fiction novels and films have used aspects of genetics as plot devices, often taking one of two routes: a genetic accident with disastrous consequences; or, the feasibility and desirability of a planned genetic alteration. The treatment of science in these stories has been uneven and often unrealistic. The film Gattaca did attempt to portray science accurately but was criticised by scientists.

Modern genetics began with the work of the monk Gregor Mendel in the 19th century, on the inheritance of traits in pea plants. Mendel found that visible traits, such as whether peas were round or wrinkled, were inherited discretely, rather than by blending the attributes of the two parents.[1] In 1900, Hugo de Vries and other scientists rediscovered Mendel's research; William Bateson coined the term "genetics" for the new science, which soon investigated a wide range of phenomena including mutation (inherited changes caused by damage to the genetic material), genetic linkage (when some traits are to some extent inherited together), and hybridisation (crosses of different species).[2]

Eugenics, the production of better human beings by selective breeding, was named and advocated by Charles Darwin's cousin, the scientist Francis Galton, in 1883. It had both a positive aspect, the breeding of more children with high intelligence and good health; and a negative aspect, aiming to suppress "race degeneration" by preventing supposedly "defective" families with attributes such as profligacy, laziness, immoral behaviour and a tendency to criminality from having children.[3][4]

Molecular biology, the interactions and regulation of genetic materials, began with the identification in 1944 of DNA as the main genetic material;[5] the genetic code and the double helix structure of DNA was determined by James Watson and Francis Crick in 1953.[6][7] DNA sequencing, the identification of an exact sequence of genetic information in an organism, was developed in 1977 by Frederick Sanger.[8]

Genetic engineering, the modification of the genetic material of a live organism, became possible in 1972 when Paul Berg created the first recombinant DNA molecules (artificially assembled genetic material) using viruses.[9]

Cloning, the production of genetically identical organisms from some chosen starting point, was shown to be practicable in a mammal with the creation of Dolly the sheep from an ordinary body cell in 1996 at the Roslin Institute.[10]

Mutation and hybridisation are widely used in fiction, starting in the 19th century with science fiction works such as Mary Shelley's 1818 novel Frankenstein and H. G. Wells's 1896 The Island of Dr Moreau.[11]

In her 1977 Biological Themes in Modern Science Fiction, Helen Parker identified two major types of story: "genetic accident", the uncontrolled, unexpected and disastrous alteration of a species;[12][13] and "planned genetic alteration", whether controlled by humans or aliens, and the question of whether that would be either feasible or desirable.[12][13] In science fiction up to the 1970s, the genetic changes were brought about by radiation, breeding programmes, or manipulation with chemicals or surgery (and thus, notes Lars Schmeink, not necessarily by strictly genetic means).[13] Examples include The Island of Dr Moreau with its horrible manipulations; Aldous Huxley's 1932 Brave New World with a breeding programme; and John Taine's 1951 Seeds of Life, using radiation to create supermen.[13] After the discovery of the double helix and then recombinant DNA, genetic engineering became the focus for genetics in fiction, as in books like Brian Stableford's tale of a genetically modified society in his 1998 Inherit the Earth, or Michael Marshall Smith's story of organ farming in his 1997 Spares.[13]

Comic books have imagined mutated superhumans with extraordinary powers. The DC Universe (from 1939) imagines "metahumans"; the Marvel Universe (from 1961) calls them "mutants", while the Wildstorm (from 1992) and Ultimate Marvel (20002015) Universes name them "posthumans".[14] Stan Lee introduced the concept of mutants in the Marvel X-Men books in 1963; the villain Magneto declares his plan to "make Homo sapiens bow to Homo superior!", implying that mutants will be an evolutionary step up from current humanity. Later, the books speak of an X-gene that confers powers from puberty onwards. X-men powers include telepathy, telekinesis, healing, strength, flight, time travel, and the ability to emit blasts of energy. Marvel's god-like Celestials are later (1999) said to have visited Earth long ago and to have modified human DNA to enable mutant powers.[15]

James Blish's 1952 novel Titan's Daughter (in Kendell Foster Crossen's Future Tense collection) featured stimulated polyploidy (giving organisms multiple sets of genetic material, something that can create new species in a single step), based on spontaneous polyploidy in flowering plants, to create humans with more than normal height, strength, and lifespans.[16]

Cloning, too, is a familiar plot device. Aldous Huxley's 1931 dystopian novel Brave New World imagines the in vitro cloning of fertilised human eggs.[17][18] Huxley was influenced by J. B. S. Haldane's 1924 non-fiction book Daedalus; or, Science and the Future, which used the Greek myth of Daedalus to symbolise the coming revolution in genetics; Haldane predicted that humans would control their own evolution through directed mutation and in vitro fertilisation.[19] Cloning was explored further in stories such as Poul Anderson's 1953 UN-Man.[20] In his 1976 novel, The Boys from Brazil, Ira Levin describes the creation of 96 clones of Adolf Hitler, replicating for all of them the rearing of Hitler (including the death of his father at age 13), with the goal of resurrecting Nazism. In his 1990 novel Jurassic Park, Michael Crichton imagined the recovery of the complete genome of a dinosaur from fossil remains, followed by its use to recreate living animals of an extinct species.[11]

Cloning is a recurring theme in science fiction films like Jurassic Park (1993), Alien Resurrection (1997), The 6th Day (2000), Resident Evil (2002), Star Wars: Episode II (2002) and The Island (2005). The process of cloning is represented variously in fiction. Many works depict the artificial creation of humans by a method of growing cells from a tissue or DNA sample; the replication may be instantaneous, or take place through slow growth of human embryos in artificial wombs. In the long-running British television series Doctor Who, the Fourth Doctor and his companion Leela were cloned in a matter of seconds from DNA samples ("The Invisible Enemy", 1977) and thenin an apparent homage to the 1966 film Fantastic Voyageshrunk to microscopic size in order to enter the Doctor's body to combat an alien virus. The clones in this story are short-lived, and can only survive a matter of minutes before they expire.[21] Films such as The Matrix and Star Wars: Episode II Attack of the Clones have featured human foetuses being cultured on an industrial scale in enormous tanks.[22]

Cloning humans from body parts is a common science fiction trope, one of several genetics themes parodied in Woody Allen's 1973 comedy Sleeper, where an attempt is made to clone an assassinated dictator from his disembodied nose.[23]

Genetic engineering features in many science fiction stories.[16] Films such as The Island (2005) and Blade Runner (1982) bring the engineered creature to confront the person who created it or the being it was cloned from, a theme seen in some film versions of Frankenstein. Few films have informed audiences about genetic engineering as such, with the exception of the 1978 The Boys from Brazil and the 1993 Jurassic Park, both of which made use of a lesson, a demonstration, and a clip of scientific film.[11][24] In 1982, Frank Herbert's novel The White Plague described the deliberate use of genetic engineering to create a pathogen which specifically killed women.[16] Another of Herbert's creations, the Dune series of novels, starting with Dune in 1965, emphasises genetics. It combines selective breeding by a powerful sisterhood, the Bene Gesserit, to produce a supernormal male being, the Kwisatz Haderach, with the genetic engineering of the powerful but despised Tleilaxu.[25]

Genetic engineering methods are weakly represented in film; Michael Clark, writing for The Wellcome Trust, calls the portrayal of genetic engineering and biotechnology "seriously distorted"[24] in films such as Roger Spottiswoode's 2000 The 6th Day, which makes use of the trope of a "vast clandestine laboratory ... filled with row upon row of 'blank' human bodies kept floating in tanks of nutrient liquid or in suspended animation". In Clark's view, the biotechnology is typically "given fantastic but visually arresting forms" while the science is either relegated to the background or fictionalised to suit a young audience.[24]

Eugenics plays a central role in films such as Andrew Niccol's 1997 Gattaca, the title alluding to the letters G, A, T, C for guanine, adenine, thymine, and cytosine, the four nucleobases of DNA. Genetic engineering of humans is unrestricted, resulting in genetic discrimination, loss of diversity, and adverse effects on society. The film explores the ethical implications; the production company, Sony Pictures, consulted with a gene therapy researcher, French Anderson, to ensure that the portrayal of science was realistic, and test-screened the film with the Society of Mammalian Cell Biologists and the American National Human Genome Research Institute before its release. This care did not prevent researchers from attacking the film after its release. Philim Yam of Scientific American called it "science bashing"; in Nature Kevin Davies called it a ""surprisingly pedestrian affair"; and the molecular biologist Lee Silver described the film's extreme genetic determinism as "a straw man".[26][27]

The geneticist Dan Koboldt observes that while science and technology play major roles in fiction, from fantasy and science fiction to thrillers, the representation of science in both literature and film is often unrealistic.[28] In Koboldt's view, genetics in fiction is frequently oversimplified, and some myths are common and need to be debunked. For example, the Human Genome Project has not (he states) immediately led to a Gattaca world, as the relationship between genotype and phenotype is not straightforward. People do differ genetically, but only very rarely because they are missing a gene that other people have: people have different alleles of the same genes. Eye and hair colour are controlled not by one gene each, but by multiple genes. Mutations do occur, but they are rare: people are 99.99% identical genetically, the 3 million differences between any two people being dwarfed by the hundreds of millions of DNA bases which are identical; nearly all DNA variants are inherited, not acquired afresh by mutation. And, Koboldt writes, believable scientists in fiction should know their knowledge is limited.[29]

See original here:
Genetics in fiction - Wikipedia

Posted in Genetic Engineering | Comments Off on Genetics in fiction – Wikipedia

Page 219«..1020..218219220221..230240..»